Previous Article | Next Article 
Journal of Virology, May 2001, p. 4681-4691, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4681-4691.2001
Transport of Human Immunodeficiency Virus Type 1 Pseudoviruses
across the Blood-Brain Barrier: Role of Envelope Proteins and
Adsorptive Endocytosis
William A.
Banks,1,*
Eric O.
Freed,2
Kathleen M.
Wolf,1
Sandra M.
Robinson,1
Mark
Franko,1 and
Vijaya B.
Kumar1
GRECC, Veterans Affairs Medical Center
St.
Louis, and Division of Geriatrics, Department of Internal Medicine,
Saint Louis University School of Medicine, St. Louis,
Missouri,1 and Laboratory of Molecular
Microbiology, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda,
Maryland2
Received 27 November 2000/Accepted 22 February 2001
 |
ABSTRACT |
Blood-borne human immunodeficiency virus type 1 (HIV-1) crosses the
blood-brain barrier (BBB) to induce brain dysfunction. How HIV-1
crosses the BBB is unclear. Most work has focused on the ability of
infected immune cells to cross the BBB, with less attention devoted to
the study of free virus. Since the HIV-1 coat glycoprotein gp120 can
cross the BBB, we postulated that gp120 might be key in determining
whether free virus can cross the BBB. We used radioactive virions which
do (Env+) or do not (Env
) bear the envelope
proteins to characterize the ability of HIV-1 to be taken up by the
murine BBB. In vivo and in vitro studies showed that the envelope
proteins are key to the uptake of free virus and that uptake was
enhanced by wheat germ agglutinin, strongly suggesting that the
envelope proteins induce viral adsorptive endocytosis and transcytosis
in brain endothelia. Capillary depletion showed that Env+
virus completely crossed the vascular BBB to enter the parenchyma of
the brain. Virus also entered the cerebrospinal fluid, suggesting passage across the choroid plexus as well. About 0.22% of the intravenously injected dose was taken up per g of brain. In vitro studies showed that postinternalization membrane cohesion (membrane binding not reversed with acid wash or cell lysis) was a regulated event. Intact virus was recovered from the brain endothelial cytosol and was effluxed from the endothelial cells. These results show that
free HIV-1 can cross the BBB by an event related to adsorptive endocytosis and mediated by the envelope proteins.
 |
INTRODUCTION |
Human immunodeficiency virus type 1 (HIV-1) produces clinically significant effects on brain function in
about 25% of patients with AIDS. These effects range from cognitive
impairments to central diabetes insipidus (29, 34). Entry
of virus into the central nervous system (CNS) occurs early in the
course of HIV-1 infection, predating neurological symptoms and even
seroconversion in some patients (1, 59). HIV-1 does not
infect neurons and is thought to produce its effects by infecting
microglia and astrocytes (1, 3, 64).
To produce these effects on brain, HIV-1 must cross the blood-brain
barrier (BBB). Disruption of the BBB is minimal in AIDS (21, 31,
56), and so the virus must negotiate a BBB that is largely
intact. Several mechanisms have been suggested for how HIV-1 could
cross the BBB (6). One mechanism is that HIV, like
togavirus, murine retrovirus, and mumps virus, could first infect the
cells which comprise the BBB. HIV-1 has been reported to infect both
the brain endothelial cells (1, 3, 55, 64), which comprise
the vascular arm of the BBB, and the choroid plexus, which forms the
blood-cerebrospinal fluid (CSF) barrier (3, 22). In vitro
studies have shown that HIV-1 can infect brain endothelial cells
(47-49).
The "Trojan horse" mechanism postulates that infected macrophages
cross-activated brain endothelial cells to take up residence in the CNS
as infected microglial cells (51, 53). Brain endothelial cells and immune cells activated by cytokines or infection overexpress adhesion molecules and their ligands, promoting the binding of circulating immune cells to brain vasculature (36). Such
binding could be the first step in diapedesis, the passage of immune
cells across the BBB (44). This close proximity could also
facilitate the passage of virus between the infected immune cell and
the brain endothelial cell, analogous to the transfer of virus between infected immune cells and epithelial cells (14).
Finally, free virus may also cross the BBB. Fewer data exist on this
mechanism, possibly due to the difficulty of studying virus in
available models. HIV-1 has been shown in vitro to cross brain
endothelial cell monolayers by mechanisms enhanced by tumor necrosis
factor alpha and cocaine (16, 69).
The mechanisms by which HIV enters the brain is important. The model
for passage of infected immune cells across the BBB has emphasized the
CNS as a reservoir of virus for the reinfection of the periphery and
mechanisms for neuronal loss and immune cell invasion to explain CNS
dysfunction. The ability of cell-free virus to cross the BBB, in
contrast, could emphasize the periphery as a continuous source for
viral presentation to the CNS. Although free virus that had crossed the
BBB would then be available to infect microglia and astrocytes, this
model would be more consistent with recent observations suggesting that
a large component of neuroAIDS is due to a metabolic encephalopathy
that can be reversed when the peripheral viral load is decreased
(27).
We have proposed that gp120 could be an important and unifying element
for the several mechanisms by which HIV-1 has been suggested to cross
the BBB (5). The HIV-1 glycoproteins are initially
expressed as a polyprotein precursor, gp160, which is cleaved during
transport to the cell surface to generate the surface glycoprotein
gp120 and the transmembrane glycoprotein gp41. HIV-1 expresses as its
viral coat the glycoprotein complex gp160, which is comprised of the
integral membrane protein gp41 noncovalently bound to gp120. It is
gp120 which binds to the CD4 receptor and coreceptor to initiate
membrane fusion and entry into CD4+ cell types
(24). In some cells, gp120 binds to galactosylcerimide binding sites (24). However, CD4 and galactosylcerimide
are absent from brain endothelial cells (47), and so how
gp120 could initiate viral uptake or facilitate the uptake of infected
immune cells which express gp120 is not clear. Other glycoproteins,
exemplified by wheat germ agglutinin (WGA), can cross the BBB by
inducing a vesicular process termed adsorptive endocytosis (15,
61). Adsorptive endocytosis, therefore, provides a classic
mechanism by which a glycoprotein like gp120 can interact with the BBB
to induce a vesicular pathway for the uptake and transport of virus across the BBB. Adsorptive endocytosis could also be a mechanism for
cell to cell transmission of virus, a process dependent on gp120 and
stimulated by WGA (19). We have shown gp120 itself crosses
the BBB by a process which resembles adsorptive endocytosis, with
enhancement of passage by WGA (7, 10, 11). Whether gp120
is important in the uptake by the brain of either free virus or
infected immune cells is unclear.
Here we studied the transport across the BBB of radioactively labeled
HIV-1 pseudoviruses after intravenous (i.v.) injection into mice. We
determined the role of the gp120-gp41 complex by studying viruses which
did (Env+) or did not (Env
) bear envelope
proteins. We also studied in vitro the ability of brain endothelial
cells to take up and internalize virus and the ability of the virus to
cohere to the membranes of the brain endothelial cell.
 |
MATERIALS AND METHODS |
Viral propagation.
The plasmid construct for pNL4-3KFS was
made by introducing an insertion at the 5' end of the env
gene which produced a frameshift, thereby preventing Env protein
expression (25). HeLa cell expression produces
noninfectious virus particles lacking gp120/gp41 (Env
).
When pNL4-3KFS is cotransfected with the T-cell-tropic Env expression
plasmid pIII4-3env (50), the virions produced contained envelope proteins but still lacked a functional env gene
(Env+). Virus was separated from cells by centrifugation at
1,000 × g for 30 min, and the virus was then pelleted
from this supernatant by ultracentrifugation at 105,000 × g for 2 h.
Radioactive labeling.
The Env+ and
Env
pseudoviruses, recombinant glycoprotein
gp120SF (AIDS Reagent Program, Rockville, Md.), and bovine
serum albumin (BSA; Sigma Chemical Co., St. Louis, Mo.) were labeled by
the chloramine T method (excluding the sodium metabisulfite treatment), a method which can preserve viral infectivity and viral coat protein activity (26, 46). One millicurie of 131I (New
England Nuclear, Boston, Mass.), 10 µg of chloramine T, and 5.0 µg
of protein (virus or gp120) were incubated together for 60 s.
125I was used to label albumin. The iodinated materials
were purified by filtration on G-10 Sephadex (Sigma) columns.
Incorporation of the radioactive I, as determined by trichloroacetic
acid-brine precipitation, was greater than 90% for all materials, and
the specific activities were estimated to be between 50 and 150 Ci/g of protein.
Determination of brain/serum ratios.
Male CD-1
mice (Charles River Laboratories, Wilmington, Mass.) weighing 20 to
30 g were anesthetized with an intraperitoneal injection of 40%
ethyl carbamate. The left jugular vein and right carotid artery were
isolated. A volume of 0.2 ml of 1% BSA in lactated Ringer's solution
was injected into the jugular vein. The injection contained
106 cpm of I-Env+ or I-Env
virus.
Some injections also contained 125I-labeled albumin (I-Alb)
or WGA (10 µg/mouse; Sigma). Between 1 and 180 min after injection,
blood was obtained from the carotid artery, and the mouse was
decapitated. The brain was removed, the pineal and pituitary glands
were discarded, and the remainder was weighed; levels of radioactivity
were determined in a dual gamma counter that can differentiate
125I and 131I. The whole blood was centrifuged
at 5,000 × g for 10 min at 4°C, and the level of
radioactivity in the resulting serum was determined. The brain/serum
ratio was calculated as (cpm/g of brain)/(cpm/µl of serum).
Measurement of unidirectional influx rate.
The permeability
of the BBB to virus was measured by determining the blood-to-brain
influx rate (Ki, in microliters per gram per
minute) by multiple-time regression analysis. To adjust for the
clearance of virus and I-Alb from the blood, exposure time (Expt) was calculated from the equation (13,
52) Expt = [
0tCp(
)d
]/Cpt,
where Cpt is the level of radioactivity in serum at time
t and
is the dummy variable for time. Brain/serum ratios were plotted against Expt, and the regression line for the
linear portion of the relation was calculated. The slope of this
relation measures Ki, and the intercept measures
the distribution volume within brain at t = 0
(Vi, in microliters per gram). Lack of a statistically significant relation between the brain/serum ratios and
Expt indicates either that the substance does not cross the BBB or that a steady-state between influx and efflux has already been reached.
Calculation of the percentage of injected material taken up by
the brain.
The clearance of virus from blood was first
characterized. The amount of radioactivity injected i.v. was divided by
the level of radioactivity in serum to yield the percentage of injected radioactivity (%Inj) present in 1 ml of serum: %Inj/ml = 100(cpm/ml of serum)/(cpm of injected radioactivity).
To calculate the percentage of the injected dose entering 1 g of
brain, the %Inj/ml was divided by 1,000 to convert it to percent
injected per microliter. The brain/serum ratios for virus were
corrected for vascular contamination by subtracting the brain/serum ratio for albumin (10 µl/g). The resulting brain/serum ratio was then
multiplied by percent injected per microliter to yield percent injected
per gram.
Capillary depletion.
To determine whether virus completely
crossed the BBB, we performed capillary depletion with the protocol
adapted to mice (30) from rats (60). CD-1
male mice anesthetized with intraperitoneal ethyl carbamate received an
i.v. injection of 0.2 ml of lactated Ringer's solution containing 1%
BSA, 3 × 106 cpm of virus, and 3 × 106 cpm of I-Alb. Blood from the abdominal aorta was
collected, and the cerebral cortex was removed 60 min after i.v.
injection. The cerebral cortex was weighed and emulsified with a glass
homogenizer (10 strokes) in 0.8 ml of physiological buffer (10 mM
HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM
MgSO4, 1 mM NaH2PO4, 10 mM
D-glucose [adjusted to pH 7.4]). Dextran solution (1.6 ml
of a 26% solution) was added to the homogenate, which was vortexed and
homogenized again (three strokes). Homogenization was performed at
4°C in less than 1 min. An aliquot of the homogenate was centrifuged at 5,400 × g for 15 min at 4°C in a Beckman TL-100
ultracentrifuge with a TLS-55 swinging-bucket rotor. The pellet
containing the brain vasculature and the supernatant containing the
brain parenchyma were carefully separated. The levels of radioactivity
in these fractions and in the aortic serum were determined in a gamma
counter. The fractions were expressed as volumes of distribution in
microliters per gram, and the parenchymal fraction for virus was
corrected for vascular contamination by subtracting the value for the
parenchymal fraction for albumin (Pv). The amount of virus retained by
brain capillaries (V) was measured by the volume of distribution for the vascular fraction from this experiment.
In another group of mice, the vascular space was washed out to rid the
brain of any labeled virus that might be loosely adhering
to the
luminal side of the capillaries. Sixty minutes after the
i.v.
injection, the abdominal aorta was severed and arterial blood
was
collected. The thorax was then opened to expose the heart,
both jugular
veins were severed, the descending thoracic aorta
was clamped, and 20 ml of lactated Ringer's solution injected
into the left ventricle of
the heart within about 1 min. The cerebral
cortex and serum were
obtained and processed as described above
to obtain parenchyma and
brain vasculature fractions. The washed-out
parenchyma fraction for
virus was corrected by subtracting the
parenchyma value for albumin
(Pvw). The amount of virus which
had crossed the BBB to enter the
parenchyma space of the brain
was measured by Pvw. The amount of virus
reversibly bound by brain
vasculature is given by subtracting Pvw from
Pv. The total amount
of virus exceeding the vascular space of the brain
(defined here
as the albumin space) is Pv plus
V.
Collection of CSF.
Each of the mice anesthetized with ethyl
carbamate received an i.v. injection of 13 × 106 cpm
of I-Env+ virus and 13 × 106 cpm of
I-Alb. Sixty minutes later, the scalp was removed from the posterior
aspect of the head, exposing the muscles overlying the posterior fossa.
A 30-gauge needle connected to a length of PE-10 tubing was inserted
into the posterior fossa with the head in a dependent position. CSF was
collected into the PE-10 tubing by capillary action. After collection
of about 10 µl of CSF, the tubing was removed, arterial blood was
collected from the previously exposed carotid artery, the mouse was
decapitated, and the whole brain was removed. The exact amount of CSF
(in microliters) collected was determined by measuring the length (in
centimeters) of PE-10 tubing filled with CSF and multiplying by 0.668 (the internal volume of 1 cm of PE-10 tubing is 0.668 µl). Only CSF
that was absolutely clear was analyzed. The CSF, brain, and serum were counted in a gamma counter. The results were expressed as brain/serum (microliters per gram), CSF/serum (microliters per milliliter), and
brain/CSF (milliliters per gram) ratios.
Isolation of brain microvessels.
Murine cerebral
microvessels were isolated by a modification of a method of Gerhart et
al. (28) All reagent volumes were proportionately adjusted
for the quantity of tissue processed; unless otherwise noted, all
reagents were of cell culture quality and obtained from Sigma. All
glassware and plastics were precoated with phosphate-buffered solution
containing 1% BSA to minimize adhesion and to maximize recovery of
microvessels. Briefly, 8 to 10 cerebral cortexes from adult male CD-1
mice were pooled and homogenized in cold stock buffer (25 mM HEPES, 1%
dextran in minimum essential medium [Gibco BRL, Grand Island, N.Y.]
[pH 7.4]) on ice. The homogenate was then filtered through a series of nylon mesh membranes (300-µm pore size, followed by twice through 100-µm pore size; Spectrum, Houston, Tex.), mixed with an equal volume of 40% dextran in stock buffer, and centrifuged at
5,000 × g for 15 min at 4°C. The supernatant with a
lipid layer was discarded, and the pellet was resuspended in stock
buffer and filtered through a 25-µm-pore-size nylon mesh membrane
(Bio-Design, Carmel, N.Y.). The microvessels were washed from the
surface of the membrane with stock buffer four times, collected, and
centrifuged at 5,000 × g for 15 min at 4°C. They
were resuspended in incubation buffer (129 mM NaCl, 2.5 mM KCl, 7.4 mM
Na2HPO4, 1.3 mM KH2PO4, 0.63 mM CaCl2, 0.74 mM MgSO4, 5.3 mM glucose,
0.1 mM ascorbic acid [pH 7.4]), a small aliquot being reserved for
verification of an enriched microvessel preparation by light
microscopy. About 97.5% of the cells isolated are capillary
endothelial cells, 1.6% are fibroblast-like cells, 0.9% are
erythrocytes, and there are no glia, neurons, synaptosomes, or synaptic
complexes, although there are some other membrane profiles and myelin
fragments (39).
Uptake of virus by IBM.
Isolated brain microvessels (IBM)
were resuspended in fresh incubation buffer containing 1% BSA
(2) to a concentration of about 2.5 mg of capillary
protein/ml. Duplicate volumes of 45 µl (100 µg of microvessel
protein) were mixed with 11 µl of incubation buffer containing any
additives and 4 µl of buffer containing 105 cpm of
I-Env+ virus (final volume of 60 µl). At time zero
(addition of I-Env+ virus), tubes were mixed and incubated
at 37°C for 15 min unless otherwise indicated in Results.
Microvessels were centrifuged at 10,000 × g for 2 min
at 4°C in a microcentrifuge, and the supernatants were collected. The
pellets were washed with 400 µl of incubation buffer and centrifuged
at 10,000 × g for 2 min at 4°C; this supernatant was
added to the previous one. Both the combined supernatant (S) and the
pellet (P) were counted in a gamma counter for 1 min. The percentage of
total binding is taken as 100(P)/(S + P).
When measures in addition to percentage of total binding were made, the
microvessel pellets resulting from the second incubation
buffer wash
were subjected to an acid wash procedure in which
400 µl of cold acid
wash buffer (0.028 M sodium acetate, 0.12
M NaCl, 0.02 M sodium
barbital [pH 3.0]) was added to resuspend
the pellets, followed by a
6-min incubation on ice. The tubes
were then centrifuged at
10,000 ×
g for 2 min at 4°C, and the
supernatants
were removed, and the level of radioactivity was
determined in a gamma
counter. The radioactivity in these tubes
was taken to represent
binding to the surface of the IBM that
was reversible. Acid-washed
microvessels were lysed according
to the method of Lidinsky and Drewes
(
41). Acid-washed microvessel
pellets were resuspended in
400 µl of distilled water containing
1% BSA and agitated for 2 h at 4°C. They were centrifuged at 15,000
×
g for 15 min at 4°C, supernatants were removed and saved, and
pellets were
resuspended and agitated for 1 h at 4°C. After centrifugation
at
15,000 ×
g for 15 min at 4°C, the supernatants were
pooled
with those from the first centrifugation. The level of
radioactivity
in the pooled supernatants (cytoplasmic fraction
[
C]) and in the
pellet (membrane fraction
[
M]) were determined in a gamma counter.
Calculations for
the various parameters were made as follows:
total counts internalized
(I) = C + M; total binding (TB) = I
+ reversible
binding (RB); and total counts (TC) added to the
tube = TB + S, where S is the combined supernatant of the initial
wash as defined
above. The parameters submitted to statistical
analysis were %TB = 100(TB)/TC; %RB = 100(RB)/TC; %I = 100(I)/TC;
and
%M = 100(M)/I.
Efflux of virus from IBM.
I-Env+ virus and IBM
were incubated together at 37°C for 15 min. The mixture was then
centrifuged in a microcentrifuge, the supernatants were removed, 400 µl of nonradioactive buffer was added to wash the pellets, and the
mixture was centrifuged again. The pelleted cells were resuspended in
400 µl of fresh buffer containing no radioactivity and incubated at
37°C. At 15-min intervals for the next 1 h, these cells were
repelleted, the supernatant (efflux supernatants) was collected, and
the cells were resuspended in fresh, nonradioactive buffer and
incubated at 37°C. The cells were collected after the last efflux
supernatant was removed. The level of radioactivity in the cells and
efflux supernatants was determined in a gamma counter. The amount of
radioactivity available in the cells for efflux at time zero was
determined by adding the amounts of radioactivity present in the cells
at the end of the study to the total amount of radioactivity effluxed. Results were expressed as the percentage of this number.
Identification of radioactive material recovered from biological
specimens.
The radioactivity in the cell cytoplasm and effluxed by
brain endothelial cells was characterized by two methods to determine whether it represented intact virus or shed proteins. The first method
was to use a 4B-200 Sepharose column to separate virus, gp120, and
smaller proteins based on molecular weight, with
higher-molecular-weight substances eluting in earlier fractions. The
elution profiles of radioactively labeled virus and gp120 were
determined for a 4B-200 Sepharose (Sigma) column by eluting with
100-µl aliquots of 0.25 M phosphate buffer. The elution profile of
albumin was determined with methylene blue incubated with a 1% BSA
solution in 0.25 M phosphate buffer. Peaks eluted at fractions 8 to 9 for the virus, at fractions 16 to 17 for gp120, and at fractions 21 to
22 for albumin.
The second characterization method was microcentrifugation
(
65). Radioactivity was placed in 1 ml of a 12% sucrose
solution
in 0.25 M phosphate buffer, thoroughly mixed, and centrifuged
at 20,800 ×
g at 4°C for 2 h. Before and after
centrifugation,
a 100-µl aliquot was removed and counted. The
percentage of material
pelleted was determined as [1

(postcentrifugation cpm/precentrifugation
cpm)] × 100. The
proportion of material pelleted were 64.4% ±
4.0% for freshly
iodinated virus and 16.5% ± 2.2% for freshly
labeled
gp120.
Statistics.
Means are reported with their n
values and standard error of the mean and compared by analysis of
variance. Analyses of groups of more than two means were followed by
Duncan's or Newman-Keuls posttest, and the P values were
reported for relevant statistically significant differences. Regression
lines also were calculated by the least squares method with the Prism
3.0 program (GraphPad, Inc., San Diego, Calif.) and are reported with
their slopes, intercepts, the error terms (standard deviation of the
mean) for the slopes and intercepts, the number of points on which the
regression is based (n), the correlation coefficient
(r), and the level of significance for the correlation
(P). Regression lines were compared for statistical differences with the Prism 3.0 program, which first determines whether
there are differences between slopes and, if there are not, whether
there are differences between intercepts.
 |
RESULTS |
In vivo analyses.
Both Env+ and Env
viruses and albumin had measurable rates of passage from blood to
brain, as demonstrated by statistically significant relations between
their brain/serum ratios and Expt (I-Env+ virus,
n = 10, r = 0.951, P < 0.0001;
I-Env
virus, n = 12, r = 0.958, P < 0.0001; I-Alb, n = 8, r = 0.850, P < 0.01) (Fig. 1). The rate of passage
as measured by the unidirectional influx rate
(Ki) for Env+ virus was 0.228 ± 0.026 µl/g/min. This was over five times greater than the
Ki for I-Alb of 0.034 ± 0.008 µl/g/min
and was statistically different from it: F(1,14) = 38.9, P < 0.0001. The Ki for Env
virus was
0.058 ± 0.005 µl/g/min and was statistically different from the
Ki for I-Env+ virus
[F(1,19) = 59.5, P < 0.001] but not for I-Alb.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Transport of Env+ virus, Env
virus, and albumin across the BBB. The transport of Env+
virus was faster than that of either albumin or Env
virus. There was no statistically significant difference in the rate of
transport of Env versus that of albumin.
|
|
Viral clearance from blood followed a two-phase distribution pattern
(Fig.
2). An early distribution phase
occurred for the
earliest time points (3 min or less), after which a
plateau phase
was reached. For Env
+ virus, this plateau
gave a value of about 8% Inj/ml (Fig.
2A),
or a volume of distribution
of about 12.5 ml. For Env

virus, the plateau was about
20% (Fig.
2B), giving a volume of
distribution of 5 ml, or a little
over twice the vascular space
of the mouse. Injection of WGA did not
affect viral clearance
except to increase the earliest time point.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 2.
Clearance of virus from blood after i.v. injection. (A)
Clearance of Env+ virus. WGA had little effect on
clearance. (B) Clearance of Env virus. WGA had little
effect on clearance. Env+ (no WGA) is shown for
reference.
|
|
The level of injected Env
+ virus in the brain peaked at
about 0.22%/g of brain (Fig.
3). The
peak occurred 60 min after injection
and remained stable for 180 min
after i.v. injection.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Percentage of an i.v. dose of Env+ virus
taken up per gram of brain. Results have been corrected for the
vascular space of the brain. Peak value was about 0.22%/g.
|
|
WGA acutely increased the uptake of Env
+ virus but had no
effect on Env

virus (Fig.
4), consistent with a role for adsorptive
endocytosis
in viral uptake. Figure
4A shows a pilot study which
indicated
that WGA produced an immediate, short-term increase in the
uptake
of Env
+ virus as previously seen for gp120. WGA had
no statistically
significant effect on Env

virus. Values
below zero show when brain/serum ratios for virus
were lower than those
for coinjected I-Alb. Figure
4B shows results
for mice that received an
i.v. injection containing I-Env
+ or I-Env

virus and I-Alb with or without WGA. Brain and serum were collected
5 min after i.v. injection, and the brain/serum ratios for virus
were
corrected for vascular space as measured with I-Alb. The
results show
that WGA had an effect on I-Env
+ virus uptake:
F(3,16) = 11.29,
P < 0.0005,
n = 5/group,
increasing
uptake about 15 times. The range test showed that the
I-Env
+ virus-plus-WGA group differed from the groups of
I-Env
+ virus (
P < 0.01),
I-Env

virus plus WGA (
P < 0.01), and
I-Env

virus (
P < 0.001). WGA had no
effect on Env

virus uptake; the negative values suggest
that Env

virus distributes into a slightly smaller
vascular space in the
brain than does serum albumin. No other
differences occurred among
these groups. This shows that WGA-enhanced
adsorptive endocytosis
is dependent on the presence of gp120 and gp41
envelope proteins
in HIV-1.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of WGA on virus uptake. (A) Pilot study showing
that WGA had an effect on Env+ virus uptake but not on
Env virus uptake; (B) effect of WGA on the uptake of
Env+ and Env virus 5 min after i.v.
injection. WGA produced a statistically significant enhancement of
Env+ uptake but not of Env uptake.
|
|
Capillary depletion was used to determine whether the
I-Env
+ taken up by the brain completely crossed the BBB or
was sequestered
by the capillary bed. The results showed that the
majority of
I-Env
+ virus crossed the BBB completely to
enter the brain parenchymal
space (Table
1). Smaller amounts of I-Env
+
virus (less than 1 µl/g) were reversibly bound to capillaries
or were
retained by capillaries.
CSF was collected to determine whether i.v.-injected Env
+
could enter this compartment of the CNS. The entry of
I-Env
+ virus into CSF exceeded that of I-Alb, as shown by
the CSF/serum
ratios (Fig.
5A); the
brain/serum ratios for I-Env
+ virus and I-Alb are also
shown for comparison. The I-Alb value
for brain/serum ratios represents
primarily the vascular space
of the brain. Properly collected CSF has
no vascular component,
and the albumin value for CSF/serum ratios
primarily represents
residual leakage of the BBB through extracellular
pathways (
4).
Correction of brain/serum and CSF/serum
ratios for I-Env
+ virus by subtracting the I-Alb ratios
yields more specific measures
of viral uptake, even though I-Alb is
correcting brain and CSF
for different nonspecific measures. Figure
5B
shows that the CSF/serum
and brain/serum ratios corrected for the
albumin spaces exceed
zero, demonstrating that virus enters both
compartments. The brain/CSF
ratio exceeded unity, suggesting that the
choroid plexus is less
permeable to I-Env
+ virus than is
the vascular barrier.

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 5.
Viral entry into CSF compartment after i.v. injection of
Env+. (A) Comparison of brain/serum and CSF/serum ratios;
(B) ratios corrected for albumin space. The dashed line represents
unity and shows that the albumin-corrected brain/CSF ratio is
greater than 1.
|
|
In vitro analyses.
In vitro incubation of IBM with
I-Env+ virus showed that brain microvessels took up virus
in a time-dependent manner. Figure 6A compares I-Env+ virus
uptake to I-Env
virus uptake for the first 90 min of
incubation. The percent binding of I-Env
virus averaged
1.09% ± 0.8% and did not increase over time. The highest value for
I-Env
virus was lower than the lowest value for
I-Env+ virus. This shows that Env proteins are crucial to
the specific uptake of HIV-1 by the brain endothelial cells which
comprise the BBB. Uptake of I-Env+ virus was rapid for
about 15 min (Fig. 6A) and then entered a more steady uptake phase which lasted at least 6 h (Fig. 6B). WGA
(50 µg/ml) increased greatly (three to fivefold at most time points)
the uptake of I-Env+ virus by IBM.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 6.
Percentage of total binding by IBM. (A) Comparison of
capillary binding of Env+ and Env virus (No
WGA); (B) comparison of uptake of Env+ virus incubated with
or without WGA.
|
|
We determined the fate of Env
+ virus taken up by IBM. When
cells were incubated for 2 h with I-Env
+ virus, WGA
increased the percentages of total binding, internalization,
and
reversible binding (Fig.
7A to C,
respectively) of Env
+ virus in a dose-response manner
(
n = 5/concentration). This shows
that the majority of
Env
+ taken up by IBM is internalized and very little is
loosely bound
to the surface. These results also demonstrate that WGA
promotes
this internalization. The percentage of internalized
Env
+ virus that cohered to membranes decreased in a
dose-response
manner (Fig.
7E) from 95.8 ± 0.5 with no WGA to
65.6 ± 2.4 at
1,500 µg of WGA per ml. This shows the majority
of internalized
virus is strongly integrated with, and perhaps fused
to, the membrane
compartment. The decrease in percentage of membrane
coherence
percent internalization increases shows both that
internalization
and membrane cohesion are separate processes and
suggest that
factors promoting the former are limited. Alternatively,
WGA could
inhibit membrane cohesion. The Prism software program
determined
that the two-site model was a better fit than the one-site
model
for the results shown in Fig.
7.
To determine whether increasing WGA could decrease percentage of
membrane coherence at short incubation times, an abbreviated
dose-response curve was performed at a 15-min incubation period.
WGA
once again increased percentages of total binding, internalization,
and
reversible binding (Fig.
8A to C,
respectively) in a dose-response
manner (
n = 5/concentration). Values for membrane coherence (Fig.
8D) were
similar to those in Fig.
7D, decreasing from 91.3% ±
0.3% with no
WGA to 65.3% ± 0.8% at 1,500 µg/ml of WGA.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 8.
Effect of WGA on fate of Env+ taken up by
IBM. WGA increased percentages of total binding, reversible binding,
and internalization in a dose-response manner. The percentage of
membrane coherence decreased with increasing WGA concentration. *,
P < 0.05 in comparison to no dose.
|
|
Protamine sulfate (PS) is a polycation that can induce adsorptive
endocytosis in brain endothelial cells (
62,
63) and
reverse gp120 membrane coherence (
7). We determined
whether
PS at 1 mg/ml, an optimal dose for promoting gp120 membrane
coherence
(
7), could affect the uptake, internalization,
and membrane
coherence of Env
+ virus by IBM. The results
for the effect of PS on percentages
of total binding
[
F(3,8) = 580,
P < 0.001), internalization
[
F(3,8)
= 197,
P < 0.001), reversible binding
[
F(3,8) = 6.77,
P < 0.05),
and membrane
coherence [
F(3,8) = 29.3,
P < 0.001) are shown
in
Fig.
9 (
n = 3/group).
The posttest showed that PS (1 mg/ml), WGA
(50 µg/ml), and PS plus
WGA increased percentages of total binding,
internalization, and
reversible binding all at
P < 0.05 or less.
PS
increased percentages of total binding and internalization
more than
WGA (
P < 0.001), and PS plus WGA increased these
values
more than PS or WGA alone (
P < 0.001). PS plus
WGA also increased
percentage reversible binding more than PS or WGA
alone (
P < 0.01).
These results show that both WGA and
PS alone or together promote
viral binding and internalization by IBM.
WGA and PS plus WGA
decreased the percentage of membrane coherence
(
P < 0.01), but
PS alone did not. This value was
decreased more by PS plus WGA
than by WGA alone (
P < 0.01), again showing that WGA affects percentages
of
internalization and membrane coherence differently.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 9.
Effects of WGA, PS, and PS plus WGA on fate of
Env+ virus taken up by IBM. WGA, PS, and PS plus WGA
increased percentage of total binding and internalization; the
percentage of reversible binding was increased only with PS plus WGA.
WGA and PS plus WGA but not PS alone decreased the percentage of
membrane coherence. *, P < 0.05 for indicated
comparisons.
|
|
To determine whether the radioactivity internalized by IBM represented
intact virus, we lysed the cells and submitted the
resulting cytoplasm
to Sepharose column chromatography. The radioactivity
was derived from
IBM incubated with Env
+ virus and PS plus WGA to retard
membrane coherence. The results
(Fig.
10A) showed that 50.6% of the
radioactivity eluted in the
position of virus at fractions 7 to 10. Cytosolic radioactivity
was also submitted to sucrose centrifugation;
32.1% less radioactivity
was found in the postcentrifugation phase.
This shows intact virus
can reside inside brain endothelial cells and
should be available
for either infecting the cell or being effluxed to
the luminal
or abluminal surface.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 10.
Identification of radioactivity recovered from IBM.
Radioactivity was characterized on a 4B-200 Sepharose column. The
elution peaks for virus, gp120, and albumin as determined for this type
of column are shown. (A) Characterization of radioactivity recovered
from the cytoplasm of IBM that had been incubated with Env+
virus. Over 50% eluted in the position of virus. (B) Characterization
of radioactivity effluxed by IBM that had been preincubated with
Env+ virus. About 25% of effluxed material eluted in the
position of virus, showing that intact virus survives endocytosis and
exocytosis to either the luminal or abluminal surface.
|
|
To determine whether intact virus is effluxed from IBM, we preincubated
Env
+ virus with IBM, washed and transferred the IBM to
nonradioactive
media, and collected and characterized the effluxed
radioactivity.
Efflux was greatest during the first 15 min (Table
2). About
25% of the radioactivity
effluxed during the first 15 min eluted
on Sepharose as intact virus,
with other peaks eluting in the
region of I-gp 120 and of smaller
proteins (Fig.
10B). About 96.4%
of effluxed radioactivity could be
precipitated by acid. This
shows that brain endothelial cells can
discharge intact virus
and viral proteins into their environment.
 |
DISCUSSION |
The purpose of these studies was to characterize the ability of
HIV-1 to cross the BBB as free virus. The use of pseudotyped virions
has distinct advantages for this purpose. By constructing virions with
(Env+) and without (Env
) envelope proteins,
we were able to test the hypothesis that gp120/gp41 is key to viral
uptake by the BBB. The virions, even those with envelope proteins, do
not carry the env gene and so do not produce infectious
virions. This allows us to study events related to the uptake of an
initial, exogenously administered viral load. These results, therefore,
most closely reflect events during the early stage of HIV-1 invasion
into the CNS before astrocytes and glial cells become infected. Major
findings for this study are: (i) the Env proteins are necessary for the
transport of i.v.-injected HIV-1 virions across the BBB; (ii) transport
characteristics of Env+ virus resemble adsorptive
endocytosis, including enhancement by WGA; (iii) virus likely enters
the CNS at both the vascular BBB and the choroid plexus; (iv) the
majority of virus taken up from the circulation completely crosses the
BBB to enter the parenchymal and CSF compartments of the brain; (v) in
vitro studies confirm the major in vivo findings, including the
importance of Env proteins and adsorptive endocytosis-like mechanisms
of uptake; (vi) Binding, internalization, postinternalization membrane
cohesion, and efflux are identifiable phases in the uptake of
Env+ virions by brain endothelial cells; and (vii) a
portion of the virus taken up by brain endothelial cells resides intact
in and is effluxed intact from brain endothelial cells. Taken together, these findings show that blood-borne HIV-1 is capable of crossing the
BBB. The results supporting each of these findings are discussed below.
The Env+ virus was taken up by the brain after i.v.
injection into the mouse about seven times faster than albumin even
though the virus is much larger than albumin. This shows that uptake of
virus was not due to leakage or entry of virus through the extracellular pathways but involves mechanisms for selective
permeability. Since the albumin and virus were coinjected, the
possibility that virus induced a disruption of the BBB is ruled out, as
the uptake of the smaller albumin molecule would have been at least as
great as that of virus. The uptake of Env
virus was not
statistically different from the uptake of albumin. This marked
difference between the uptake rates of Env
and
Env+ viruses shows the importance of envelope proteins in
the uptake of free virus by the BBB. This role for envelope proteins in
the uptake of free virus differs from the mechanisms proposed for the
transport across the BBB of infected immune cells, which has emphasized
the interaction of adhesion molecules and ligands (44). A
role for the envelope proteins in viral uptake is consistent with work
by others. For example, virus-sized latex particles covalently coated
with gp120 are taken up by epithelial cells (38), the C1
region of gp120 determines endothelial tropism independently of
macrophage or T-cell tropism (49), and the CD4-independent
uptake of HIV-1 by HeLa cells is gp120 dependent (45). The
presence of envelope proteins also increased the volume of distribution
after i.v. injection two- to threefold (Fig. 2), consistent with
gp120/gp41 being important for the uptake of HIV-1 by non-CNS tissues.
The percentage of Env+ virus taken up by the brain after
i.v. injection was 0.22/g of brain, a value higher than those for some
centrally active substances such as morphine (0.018%), leptin (0.17%), biphalan (0.05%), or domoic acid (0.002%) (9, 12, 35,
57). Uptake was also sustained, continuing for at least 3 h. This shows that a sizable percentage of virus can enter and be
retained by the brain.
WGA induced an acute, 15-fold increase in the uptake of
Env+ virus but had no effect on the uptake of the
Env
virus. This shows the WGA interaction was dependent
on the presence of envelope proteins and is consistent with the
adsorptive endocytosis hypothesis for HIV-1 uptake. The magnitude of
the WGA-induced increase in the uptake of Env+ virus was
similar to the 17-fold increase previously seen for free gp120
(10, 11). The ability of WGA to induce uptake of Env+ virus suggests that the gp120 portion of the
gp120/gp41 complex binds to the same sugars on the endothelial cell as
WGA (sialic acid and N-acetylglucosamine). This is
consistent with previous work with gp120, which shows that lectins
which bind to sugars other than sialic acid and
N-acetylglucosamine do not promote the transport of gp120
across the BBB (10). When WGA binds to sialic acid and
N-acetylglucosamine, it induces vesicle-mediated internalization of WGA by brain endothelial cells, termed adsorptive endocytosis (8, 17). Lectin-induced vesicles provide the basis by which enveloped viruses in general are internalized by cells
(43). Together, these results strongly suggest that gp120 or gp120/gp41 induces adsorptive endocytosis and the uptake of HIV-1 by
brain endothelial cells. Such uptake would provide a mechanism by which
brain endothelial cells could become infected with free, blood-borne virus.
Infected brain endothelial cells could infect the brain by shedding
virus from their abluminal surface into the brain interstitial fluid.
Others have suggested that replication in endothelial cells is less
important than direct viral transfer across the BBB (55). The results for capillary depletion show that Env+ virus
taken up from blood is able to completely cross the BBB. In fact, very
little Env+ virus was retained by brain endothelial cells;
most was found in the brain parenchymal fraction. These results are
similar to those previously found for free gp120. In most cases, the
material taken up by adsorptive endocytotic pathways is effluxed back
to the luminal surface of the brain endothelial cell (18, 58, 61). Other pathways route the vesicles to lysosomes, the Golgi complex, and eventually the abluminal surface of the endothelial cell.
HIV-1 has a major advantage in some of these pathways in that it is not
degraded in lysosomes (14). This work shows that at least
some of the pathways for endocytosed HIV-1 are transcytotic.
The appearance of Env+ virus in the CSF also demonstrates
that HIV-1 can enter a compartment of the CNS from the circulation. Whether virus in the CSF entered the CNS at the vascular barrier with
diffusion through the interstitial fluid to CSF or crossed at the
choroid plexus is unclear. The choroid plexus does take up HIV-1
(3, 22, 33) and is a vesicularly active tissue (37). In contrast, material transported into the CSF does
not penetrate deeply into brain tissue (42). Brain/serum
ratios, therefore, tend to reflect passage at the vascular barrier,
whereas CSF/serum ratios tend to reflect passage at the choroid plexus, especially at early time points. The brain/CSF ratio of greater than
unity has been suggested to indicate that the vascular barrier is the
major site of entry. Most likely, HIV-1 crosses at both the vascular
barrier and the choroid plexus.
The results with isolated brain microvessels confirmed and extended the
in vivo findings. Env+ virus uptake was time dependent and
enhanced by WGA. In contrast, the uptake of Env
virus was
low, did not increase with time, and was not enhanced by WGA. As with
gp120 uptake by IBM, the uptake of Env+ virus could be
divided into reversible binding, internalization, and membrane
coherence. With this method, the fate of material not effluxed to the
luminal or abluminal surfaces can be followed. Consistent with models
of adsorptive endocytosis, most of the material taken up was
internalized (as opposed to reversible cell surface binding). In
addition, almost all of the internalized material cohered to the
membrane fraction after lysis of the cells (membrane coherence). Such
coherence shows a strong association with the membranes that is likely
irreversible. Similar membrane coherence has been shown for gp120 and
is due to binding to the cell cytoskeleton (7). Whether
this membrane coherence represents viral fusion to the membrane is not
clear. The percentage of internalized material showing postlysis
membrane coherence decreased as internalization increased. This
suggests that the intracellular substrates which mediate membrane
coherence are limited relative to those which mediate internalization,
which in turn suggests that this pathway could become overwhelmed with
high viral titers in blood, which would shift more virus into the
efflux and transcytotic routes. When these experiments were repeated
after a 15-min incubation rather than 2 h, the results were nearly
identical. This indicates that consumption of the rate-limiting
membrane cohesion factor occurs rapidly. Consistent with this
possibility, about 25% of the radioactivity effluxed from IBM eluted
as free virus and the rest eluted as large proteins.
PS also can induce vesicularization of brain endothelial cells as do
many other highly charged cations (32, 62, 63). PS also
increased binding and internalization of Env+ virus. At the
concentrations tested, PS was more potent than WGA in inducing
internalization but less potent at inhibiting membrane coherence. This
demonstrates that binding and membrane coherence are separate
processes, as previously suggested from work based on gp120
(7). Consistent with this decrease in membrane coherence,
about half of the radioactivity recovered from the cytosol of these
cells eluted as intact virus.
The ability of HIV-1 to interact with murine endothelial cells raises
questions of species specificity. HIV-1 most readily infects
CD4+ primate immune cells. This species and tissue
specificity is reinforced by blocks involving membrane fusion and Tat
and Rev function (54, 66). However, neither species nor
tissue specificity is absolute, with some strains of HIV-1 better at
overcoming the blocks than others (54). Furthermore,
rabbits can become infected with HIV-1 (23) and some types
of CD4-negative cells (23, 40), and lines of rodent cells
can support HIV-1 infection (54). Human brain endothelial
cells take up HIV-1 by a CD4-independent mechanism. We have postulated
that interactions between viral and cell surface glycoproteins induce
adsorptive endocytosis in brain endothelial cells, a classic response
which provides a mechanism for the uptake and passage of HIV-1 across
the BBB. Specificity is determined by the sugars presented on the
glycoproteins. The distribution of sialic acid and
N-acetylglucosamine, the sugars to which WGA and possibly
HIV-1 envelope proteins bind, show cell type and cell surface
distribution specificity but are present on mouse, rat, and human brain
endothelial cells (8, 20, 67, 68) and could explain how
murine brain endothelial cells can readily take up a pathogen
ordinarily so restricted to infecting humans.
In conclusion, in vivo and in vitro studies show that free HIV-1 can be
taken up by brain endothelial cells and cross the BBB. The envelope
proteins are critical to this process, in that they appear to induce
adsorptive endocytosis and transcytosis.
 |
ACKNOWLEDGMENTS |
This work was supported by VA Merit Review, R0-1 MH54979, and
R0-1 NS41863.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: VAMC, 915 N. Grand Blvd., St. Louis, MO 63106. Phone: (314) 289-7084. Fax: (314)
289-6374. E-mail: bankswa{at}slu.edu.
 |
REFERENCES |
| 1.
|
An, S. F.,
M. Groves,
F. Gray, and F. Scaravilli.
1999.
Early entry and widespread cellular involvement of HIV-1 DNA in brains of HIV-1 positive asymptomatic individuals.
J. Neuropathol. Exp. Neurol.
58:1156-1162[Medline].
|
| 2.
|
Audus, K. L., and R. T. Borchardt.
1987.
Bovine brain microvessel endothelial cell monolayers as a model system for the blood-brain barrier.
Ann. N. Y. Acad. Sci.
507:9-18[Medline].
|
| 3.
|
Bagasra, O.,
E. Lavi,
L. Bobroski,
K. Khalili,
J. P. Pestaner,
R. Tawadros, and R. J. Pomerantz.
1996.
Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: indentification by the combination of in situ polymerase chain reaction and immunohistochemistry.
AIDS
10:573-585[Medline].
|
| 4.
|
Balin, B. J.,
R. D. Broadwell,
M. Salcman, and M. el-Kalliny.
1986.
Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey.
J. Comp. Neurol.
251:260-280[CrossRef][Medline].
|
| 5.
|
Banks, W. A.
1999.
Physiology and pathophysiology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders.
J. Neurovirology
5:538-555[Medline].
|
| 6.
|
Banks, W. A.
2000.
Protector, prey, or perpetrator: the pathophysiology of the blood-brain barrier in neuroAIDS.
NeuroAIDS
3:1-6. [Science Online.] www.sciencemag.org/NAIDS.
|
| 7.
|
Banks, W. A.,
V. Akerstrom, and A. J. Kastin.
1998.
Adsorptive endocytosis mediates the passage of HIV-1 across the blood-brain barrier: evidence for a post-internalization coreceptor.
J. Cell Sci.
111:533-540[Abstract].
|
| 8.
|
Banks, W. A., and R. D. Broadwell.
1994.
Blood to brain and brain to blood passage of native horseradish peroxidase, wheat germ agglutinin and albumin: pharmacokinetic and morphological assessments.
J. Neurochem.
62:2404-2419[Medline].
|
| 9.
|
Banks, W. A., and A. J. Kastin.
1994.
Opposite direction of transport across the blood-brain barrier for Tyr-MIF-1 and MIF-1: comparison with morphine.
Peptides
15:23-29[CrossRef][Medline].
|
| 10.
|
Banks, W. A., and A. J. Kastin.
1998.
Characterization of lectin-mediated brain uptake of HIV-1 gp120.
J. Neurosci. Res.
54:522-529[CrossRef][Medline].
|
| 11.
|
Banks, W. A.,
A. J. Kastin, and V. Akerstrom.
1997.
HIV-1 protein gp120 crosses the blood-brain barrier: role of adsorptive endocytosis.
Life Sci.
61:PL119-PL125[CrossRef][Medline].
|
| 12.
|
Banks, W. A.,
A. J. Kastin,
W. Huang,
J. B. Jaspan, and L. M. Maness.
1996.
Leptin enters the brain by a saturable system independent of insulin.
Peptides
17:305-311[CrossRef][Medline].
|
| 13.
|
Blasberg, R. G.,
J. D. Fenstermacher, and C. S. Patlak.
1983.
Transport of -aminoisobutyric acid across brain capillary and cellular membranes.
J. Cereb. Blood Flow Metab.
3:8-32[Medline].
|
| 14.
|
Bourinbaiar, A. S., and D. M. Phillips.
1991.
Transmission of human immunodeficiency virus from monocytes to epithelia.
J. Acquir. Immune Defic. Syndr.
4:56-63.
|
| 15.
|
Broadwell, R. D.
1989.
Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal.
Acta Neuropathol. (Berlin)
79:117-128[CrossRef][Medline].
|
| 16.
|
Broadwell, R. D.
1993.
Endothelial cell biology and the enigma of transcytosis through the blood-brain barrier.
Adv. Exp. Med. Biol.
331:137-141[Medline].
|
| 17.
|
Broadwell, R. D.,
B. J. Balin, and M. Salcman.
1988.
Transcytotic pathway for blood-borne protein through the blood-brain barrier.
Proc. Natl. Acad. Sci. USA
85:632-636[Abstract/Free Full Text].
|
| 18.
|
Broadwell, R. D., and W. A. Banks.
1993.
Cell biological perspective for the transcytosis of peptides and proteins through the mammalian blood-brain fluid barriers, p. 165-199.
In
W. M. Pardridge (ed.), The blood-brain barrier. Raven Press, Ltd., New York, N.Y.
|
| 19.
|
Busso, M.,
J. Thornthwaite, and L. Resnick.
1991.
HIV-induced syncytium formation requires the formation of conjugates between virus-infected and uninfected T-cells in vitro.
AIDS
5:1425-1432[Medline].
|
| 20.
|
Büttner, A.,
P. Mehraein, and S. Weis.
1996.
Vascular changes in the cerebral cortex in HIV-1 infection.
Acta Neuropathol.
92:35-41[CrossRef][Medline].
|
| 21.
|
Elovaara, I.,
M. Iivanainen,
S. L. Valle,
J. Suni,
T. Tervo, and J. Lahdevirta.
1987.
CSF protein and cellular profiles in various stages of HIV infection related to neurological manifestations.
J. Neurol. Sci.
78:331-342[CrossRef][Medline].
|
| 22.
|
Falangola, M. F.,
A. Hanly,
B. Galvao-Castro, and C. K. Petito.
1995.
HIV infection of human choroid plexus: a possible mechanism of viral entry into the CNS.
J. Neuropathol. Exp. Neurol.
54:497-503[Medline].
|
| 23.
|
Filice, G.,
P. M. Cereda, and O. E. Varnier.
1988.
Infection in rabbits with human immunodeficiency virus.
Nature
335:366-369[CrossRef][Medline].
|
| 24.
|
Freed, E. O., and M. A. Martin.
1995.
The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection.
J. Biol. Chem.
270:23883-23886[Free Full Text].
|
| 25.
|
Freed, E. O., and M. A. Martin.
1995.
Virion incorporation of envelope glycoproteins with long but not short cytoplasmi tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix.
J. Virol.
69:1984-1989[Abstract].
|
| 26.
|
Frost, E. H.
1977.
Radioactive labelling of viruses: an iodination preserving biological properties.
J. Gen. Virol.
35:181-185[Abstract/Free Full Text].
|
| 27.
|
Gendelman, H. E.,
J. Zheng,
C. L. Coulter,
A. Ghorpade,
M. Che,
M. Thylin,
R. Rubocki,
Y. Persidsky,
F. Hahn,
J. J. Reinhard, and S. Swindells.
1998.
Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia.
J. Infect. Dis.
178:1000-1007[Medline].
|
| 28.
|
Gerhart, D. Z.,
M. A. Broderius, and L. R. Drewes.
1988.
Cultured human and canine endothelial cells from brain microvessels.
Brain Res. Bull.
21:785-793[CrossRef][Medline].
|
| 29.
|
Grossman, D. M.,
W. A. Banks,
J. LeBlanc, and P. Dejace.
1998.
Prevalence of hypernatremia in HIV-infected VA patients.
J. Investig. Med.
46:46A.
|
| 30.
|
Gutierrez, E. G.,
W. A. Banks, and A. J. Kastin.
1993.
Murine tumor necrosis factor alpha is transported from blood to brain in the mouse.
J. Neuroimmunol.
47:169-176[CrossRef][Medline].
|
| 31.
|
Hall, C. D.,
C. R. Snyder,
K. R. Robertson,
J. A. Messenheimer,
J. W. Wilkins,
W. T. Robertson,
R. A. Whaley,
C. Van der Horst, and L. M. Silverman.
1992.
Cerebrospinal fluid analysis in human immunodeficiency virus infection.
Ann. Clin. Lab. Sci.
22:139-143[Abstract].
|
| 32.
|
Hardebo, J. E., and J. Kahrstrom.
1985.
Endothelial negative surface charge areas and blood-brain barrier function.
Acta Physiol. Scand.
125:495-499[Medline].
|
| 33.
|
Harouse, J. M.,
Z. Wroblewska,
M. A. Laughlin,
W. F. Hickey,
B. S. Schonwetter, and F. Gonzalez-Scarano.
1989.
Human choroid plexus cells can be latently infected with human immuodeficiency virus.
Ann. Neurol.
25:406-411[CrossRef][Medline].
|
| 34.
|
Harris, P. J., and R. Curry.
1995.
Diabetes insipidus and AIDS.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
9:99[CrossRef][Medline].
|
| 35.
|
Horan, P. J.,
A. Mattia,
E. J. Bilsky,
S. Weber,
T. P. Davis,
H. I. Yamamura,
E. Malatynska,
S. M. Appleyard,
J. Slaninova,
A. Misicka,
A. W. Lipkowski,
V. J. Hruby, and F. Porreca.
1996.
Antinociceptive profile of biphalin, a dimeric enkephalin analog.
J. Pharmacol. Exp. Ther.
265:1446-1454[Abstract/Free Full Text].
|
| 36.
|
Hurwitz, A. A.,
J. W. Berman, and W. D. Lyman.
1994.
The role of the blood-brain barrier in HIV infection of the central nervous system.
Adv. Neuroimmunol.
4:249-256[Medline].
|
| 37.
|
Johanson, C. E.
1988.
The choroid plexus-arachnoid membrane-cerebrospinal fluid system, p. 33-104.
In
A. A. Boulton, G. B. Baker, and W. Walz (ed.), Neuromethods; the neuronal microenvironment. The Humana Press, Clifton, N.J.
|
| 38.
|
Kage, A.,
E. Shoolian,
K. Rokos,
M. Ozel,
R. Nuck,
W. Reutter,
E. Köttgen, and G. Pauli.
1998.
Epithelial uptake and transport of cell-free human immunodeficiency virus type 1 and gp120-coated microparticles.
J. Virol.
72:4231-4236[Abstract/Free Full Text].
|
| 39.
|
Koenig, H.,
J. J. Trout,
A. D. Goldstone, and C. Y. Lu.
1992.
Capillary NMDA receptors regulate blood-brain barrier function and breakdown.
Brain Res.
588:297-303[CrossRef][Medline].
|
| 40.
|
Lafon, M. E.,
J. L. Gendrault,
C. Royer,
D. Jaeck,
A. Kirn, and A. M. Steffan.
1993.
Human endothelial cells isolated from the hepatic sinusoids and the umbilical vein display a different permissiveness for HIV-1.
Res. Virol.
144:99-104[Medline].
|
| 41.
|
Lidinsky, W. A., and L. R. Drewes.
1983.
Characterization of the blood-brain barrier: protein composition of the capillary endothelial cell membrane.
J. Neurochem.
41:1341-1348[CrossRef][Medline].
|
| 42.
|
Maness, L. M.,
W. A. Banks,
J. E. Zadina, and A. J. Kastin.
1996.
Periventricular penetration and disappearance of icv Tyr-MIF-1, DAMGO, tyrosine, and albumin.
Peptides
17:247-250[CrossRef][Medline].
|
| 43.
|
Marsh, M.
1984.
The entry of enveloped viruses into cells by endocytosis.
Biochem. J.
218:1-10[Medline].
|
| 44.
|
Miller, D. W.
1999.
Immunobiology of the blood-brain barrier.
J. Neurovirol.
5:570-578[Medline].
|
| 45.
|
Mondor, I.,
S. Ugolini, and Q. J. Sattentau.
1998.
Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.
J. Virol.
72:3623-3634[Abstract/Free Full Text].
|
| 46.
|
Montelaro, R. C., and R. R. Rueckert.
1975.
On the use of chloramine-T to iodinate specifically the surface proteins of intact enveloped viruses.
J. Gen. Virol.
29:127-131[Abstract/Free Full Text].
|
| 47.
|
Moses, A. V.,
F. E. Bloom,
C. D. Pauza, and J. A. Nelson.
1993.
Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism.
Proc. Natl. Acad. Sci. USA
90:10474-10478[Abstract/Free Full Text].
|
| 48.
|
Moses, A. V., and J. A. Nelson.
1994.
HIV infection of human brain capillary endothelial cells-Implications for AIDS dementia.
Adv. Neuroimmunol.
4:239-247[Medline].
|
| 49.
|
Moses, A. V.,
S. G. Stenglein,
J. G. Strussenberg,
K. Wehrly,
B. Chesebro, and J. A. Nelson.
1996.
Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region of the viral genome.
J. Virol.
70:3401-3406[Abstract].
|
| 50.
|
Murakami, T., and E. O. Freed.
2000.
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.
Proc. Natl. Acad. Sci. USA
97:343-348[Abstract/Free Full Text].
|
| 51.
|
Nottet, H. S.,
Y. Persidsky,
V. G. Sasseville,
A. N. Nukuna,
P. Bock,
Q. H. Zhai,
L. R. Sharer,
R. D. McComb,
S. Swindells,
C. Soderland, and H. E. Gendelman.
1996.
Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain.
J. Immunol.
156:1284-1295[Abstract].
|
| 52.
|
Patlak, C. S.,
R. G. Blasberg, and J. D. Fenstermacher.
1983.
Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.
J. Cereb. Blood Flow Metab.
3:1-7[Medline].
|
| 53.
|
Persidsky, Y.,
M. Stins,
D. Way,
M. H. Witte,
M. Weinand,
K. S. Kim,
P. Bock,
H. E. Gendelman, and M. Fiala.
1997.
A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis.
J. Immunol.
158:3499-3510[Abstract].
|
| 54.
|
Pleskoff, O.,
N. Sol,
B. Labrosse, and M. Alizon.
1997.
Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin).
J. Virol.
71:3259-3262[Abstract].
|
| 55.
|
Poland, S. D.,
G. P. Rice, and G. A. Dekaban.
1995.
HIV-1 infection of human brain-derived microvascular endothelial cells in vitro.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
8:437-445[Medline].
|
| 56.
|
Power, C.,
P.-A. Kong,
T. O. Crawford,
S. Wesselingh,
J. D. Glass,
J. C. McArthur, and B. D. Trapp.
1993.
Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier.
Ann. Neurol.
34:339-350[CrossRef][Medline].
|
| 57.
|
Preston, E., and I. Hynie.
1991.
Transfer constants for blood-brain barrier permeation of the neuroexcitatory shellfish toxin, domoic acid.
Can. J. Neurol. Sci.
18:39-44[Medline].
|
| 58.
|
Raub, T. J., and K. L. Audus.
1990.
Adsorptive endocytosis and membrane recycling by cultured primary bovine brain microvessel endothelial cell monolayers.
J. Cell Sci.
97:127-138[Abstract/Free Full Text].
|
| 59.
|
Resnick, L.,
J. R. Berger,
P. Shapshak, and W. W. Tourtellotte.
1988.
Early penetration of the blood-brain-barrier by HIV.
Neurology
38:9-14[Abstract/Free Full Text].
|
| 60.
|
Triguero, D.,
J. Buciak, and W. M. Pardridge.
1990.
Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins.
J. Neurochem.
54:1882-1888[CrossRef][Medline].
|
| 61.
|
Villegas, J. C., and R. D. Broadwell.
1993.
Transcytosis of protein through the mammalian cerebral epithelium and endothelium. II. Adsorptive transcytosis of WGA-HRP and the blood-brain and brain-blood barriers.
J. Neurocytol.
22:67-80[CrossRef][Medline].
|
| 62.
|
Vorbrodt, A. W.,
D. H. Dobrogowska,
M. Ueno, and A. S. Lossinsky.
1995.
Immunocytochemical studies of protamine-induced blood-brain barrier opening to endogenous albumin.
Acta Neuropathol. (Berlin)
89:491-499[Medline].
|
| 63.
|
Westergren, I., and B. B. Johansson.
1993.
Altering the blood-brain barrier in the rat by intracarotid infusion of polycations: a comparison between protamine, poly-L-lysine and poly-L-arginine.
Acta Physiol. Scand.
149:99-104[Medline].
|
| 64.
|
Wiley, C. A.,
R. D. Schrier,
J. A. Nelson,
P. W. Lampert, and M. B. A. Oldstone.
1986.
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.
Proc. Natl. Acad. Sci. USA
83:7089-7093[Abstract/Free Full Text].
|
| 65.
|
Willey, R. L.,
M. A. Martin, and K. W. C. Peden.
1994.
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.
J. Virol.
68:1029-1039[Abstract/Free Full Text].
|
| 66.
|
Winslow, B. J., and D. Trono.
1993.
The blocks to human immunodeficiency virus type 1 Tat and Rev functions inmouse cell lines are independent.
J. Virol.
67:2349-2354[Abstract/Free Full Text].
|
| 67.
|
Zambenedetti, P.,
R. Giordano, and P. Zatta.
1996.
Indentification of lectin binding sites in the rat brain.
Glycoconj. J.
13:341-346[CrossRef][Medline].
|
| 68.
|
Zatta, P. F.,
S. Zanoni, and M. Favarato.
1994.
Lectin histochemistry of the brain cortex in Alzheimer's disease, p. 141-153.
In
M. Nicolini, and P. F. Zatta (ed.), Glycobiology and the brain. Pergamon Press, Oxford, England.
|
| 69.
|
Zhang, L.,
D. Looney,
D. Taub,
S. L. Chang,
D. Way,
M. H. Witte,
M. C. Graves, and M. Fiala.
1998.
Cocaine opens the blood-brain barrier to HIV-1 invasion.
J. Neurovirol.
4:619-626[Medline].
|
Journal of Virology, May 2001, p. 4681-4691, Vol. 75, No. 10
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.10.4681-4691.2001
This article has been cited by other articles:
-
Stahl-Hennig, C., Kuate, S., Franz, M., Suh, Y. S., Stoiber, H., Sauermann, U., Tenner-Racz, K., Norley, S., Park, K. S., Sung, Y. C., Steinman, R., Racz, P., Uberla, K.
(2007). Atraumatic Oral Spray Immunization with Replication-Deficient Viral Vector Vaccines. J. Virol.
81: 13180-13190
[Abstract]
[Full Text]
-
Bobardt, M. D., Salmon, P., Wang, L., Esko, J. D., Gabuzda, D., Fiala, M., Trono, D., Van der Schueren, B., David, G., Gallay, P. A.
(2004). Contribution of Proteoglycans to Human Immunodeficiency Virus Type 1 Brain Invasion. J. Virol.
78: 6567-6584
[Abstract]
[Full Text]
-
Anthonypillai, C., Sanderson, R. N., Gibbs, J. E., Thomas, S. A.
(2004). The Distribution of the HIV Protease Inhibitor, Ritonavir, to the Brain, Cerebrospinal Fluid, and Choroid Plexuses of the Guinea Pig. J. Pharmacol. Exp. Ther.
308: 912-920
[Abstract]
[Full Text]
-
Moniuszko, M., Brown, C., Pal, R., Tryniszewska, E., Tsai, W.-P., Hirsch, V. M., Franchini, G.
(2003). High Frequency of Virus-Specific CD8+ T Cells in the Central Nervous System of Macaques Chronically Infected with Simian Immunodeficiency Virus SIVmac251. J. Virol.
77: 12346-12351
[Abstract]
[Full Text]
-
Gibbs, J. E., Rashid, T., Thomas, S. A.
(2003). Effect of Transport Inhibitors and Additional Anti-HIV Drugs on the Movement of Lamivudine (3TC) across the Guinea Pig Brain Barriers. J. Pharmacol. Exp. Ther.
306: 1035-1041
[Abstract]
[Full Text]
-
Patrick, M. K., Johnston, J. B., Power, C.
(2002). Lentiviral Neuropathogenesis: Comparative Neuroinvasion, Neurotropism, Neurovirulence, and Host Neurosusceptibility. J. Virol.
76: 7923-7931
[Full Text]
-
Liu, N. Q., Lossinsky, A. S., Popik, W., Li, X., Gujuluva, C., Kriederman, B., Roberts, J., Pushkarsky, T., Bukrinsky, M., Witte, M., Weinand, M., Fiala, M.
(2002). Human Immunodeficiency Virus Type 1 Enters Brain Microvascular Endothelia by Macropinocytosis Dependent on Lipid Rafts and the Mitogen-Activated Protein Kinase Signaling Pathway. J. Virol.
76: 6689-6700
[Abstract]
[Full Text]